相关实验视频

Updated: Sep 18, 2025

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

通过综合生物信息学分析方法识别CDCA4作为结直肠癌中放射治疗耐药性相关基因

Lin Chen^1,2, Yawei Gao¹, Zhiqing Hu²

¹Department of Gastrointestinal Surgery, Department of General Surgery, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200120, China.

|June 26, 2025

概括

这项研究确定了与结直肠癌 (CRC) 放射治疗耐药性相关的遗传因素和免疫细胞特征. 包括CDCA4在内的预测基因特征可能有助于为个性化治疗策略分层患者.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
免疫学免疫学免疫学

背景情况:

结肠直肠癌 (CRC) 是全球癌症死亡的主要原因.
放射治疗对于局部晚期直肠癌 (LARC) 是至关重要的,但耐药性限制了疗效.
在新辅助化学放射治疗 (nCRT) 后,很少有患者获得病理完整反应 (PCR).

研究的目的:

确定导致CRC中放射治疗耐药性的遗传和分子因素.
整合生殖基因突变,转录基因数据和免疫微环境特征.
开发放射治疗反应的预测模型.

主要方法:

在12名LARC患者的瘤中进行全外体测序 (WES).
对TCGA-READ,GSE150082和GSE190826转录组数据集的综合分析.
单细胞RNA测序 (scRNA-seq) 的 GSE132465 细胞异质性和随机森林的基因签名的发展.

主要成果:

确定了与放射治疗耐药性相关的突变格局和特定的生殖基因突变.
突出显示的DNA复制,修复和瘤免疫微环境 (TIME) 途径.
开发了一个预测基因特征 (CDCA4,FANCA,PBRM1,RPL13,C12orf43);CDCA4与TMB,MSI和B细胞透相关.

结论:

对CRC中放射治疗耐药性机制的新见解.
建议CDCA4和B细胞相关的免疫特征作为潜在的生物标志物.
表明患者分层和个性化治疗策略的实用性.

关键词:

在B细胞透的过程中.这是一个CDCA4CDCA4CDCA4CDCA4CDCA.结肠直肠癌是什么意思新辅助性化疗或放射治疗.抗辐射疗法耐药性抗辐射治疗耐药性整体外因子测序的测序

更多相关视频

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...